{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:00:47Z","timestamp":1790125247971,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":105,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10441-3","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:26:36Z","timestamp":1781112396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oxaliplatin triggers adipose and muscle wasting through cancer-independent metabolic and CNS pathways in mouse models"],"prefix":"10.1038","volume":"9","author":[{"given":"Junwei","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland C.","family":"Sudlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1717-9756","authenticated-orcid":false,"given":"Rachael L.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-7400","authenticated-orcid":false,"given":"Jonathan R.","family":"Brestoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-1195","authenticated-orcid":false,"given":"Gwendalyn J.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-2487","authenticated-orcid":false,"given":"Mikhail Y.","family":"Berezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"10441_CR1","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.2147\/CMAR.S261585","volume":"12","author":"J Ni","year":"2020","unstructured":"Ni, J. & Zhang, L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag. Res. 12, 5597\u20135605 (2020).","journal-title":"Cancer Manag. Res."},{"key":"10441_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argil\u00e9s","year":"2014","unstructured":"Argil\u00e9s, J. M., Busquets, S., Stemmler, B. & L\u00f3pez-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754\u2013762 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"10441_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","volume":"34","author":"S Blauwhoff-Buskermolen","year":"2016","unstructured":"Blauwhoff-Buskermolen, S. et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J. Clin. Oncol. 34, 1339\u20131344 (2016).","journal-title":"J. Clin. Oncol."},{"key":"10441_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/PPO.0000000000000100","volume":"21","author":"MF Penet","year":"2015","unstructured":"Penet, M. F. & Bhujwalla, Z. M. Cancer cachexia, recent advances, and future directions. Cancer J. 21, 117\u2013122 (2015).","journal-title":"Cancer J."},{"key":"10441_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153\u2013166 (2012).","journal-title":"Cell Metab."},{"key":"10441_CR6","doi-asserted-by":"publisher","first-page":"e1009505","DOI":"10.1371\/journal.pcbi.1009505","volume":"18","author":"S Farhang-Sardroodi","year":"2022","unstructured":"Farhang-Sardroodi, S., La Croix, M. A. & Wilkie, K. P. Chemotherapy-induced cachexia and model-informed dosing to preserve lean mass in cancer treatment. PLoS Comput. Biol. 18, e1009505 (2022).","journal-title":"PLoS Comput. Biol."},{"key":"10441_CR7","doi-asserted-by":"crossref","unstructured":"Cavaletti, G. & Marmiroli, P. Management of oxaliplatin-induced peripheral sensory neuropathy. Cancers (Basel) 12,1370\u20131384 (2020).","DOI":"10.3390\/cancers12061370"},{"key":"10441_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adx1436","volume":"18","author":"L-H Chen","year":"2026","unstructured":"Chen, L.-H. et al. BDNF Val66Met protects oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Sci. Transl. Med. 18, eadx1436 (2026).","journal-title":"Sci. Transl. Med."},{"key":"10441_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12035-025-05463-7","volume":"63","author":"J Du","year":"2025","unstructured":"Du, J. et al. Chronic oxaliplatin treatment induces CIPN in mice via activation of the TXNIP pathway. Mol. Neurobiol. 63, 92 (2025).","journal-title":"Mol. Neurobiol."},{"key":"10441_CR10","doi-asserted-by":"crossref","unstructured":"Du, J., Sudlow, L. C., Luzhansky, I. D. & Berezin, M. Y. DRG explant model for understanding mechanism of oxaliplatin-induced peripheral neuropathy and identifying potential therapeutic targets. Antioxidants (Basel) 15, 230\u2013246 (2026).","DOI":"10.3390\/antiox15020230"},{"key":"10441_CR11","doi-asserted-by":"crossref","unstructured":"Du, J. et al. Oxaliplatin-induced cardiotoxicity in mice is connected to the changes in energy metabolism in the heart tissue. Cardiooncology 12, 1370\u20131384, (2026).","DOI":"10.1186\/s40959-026-00453-7"},{"key":"10441_CR12","doi-asserted-by":"publisher","first-page":"C139","DOI":"10.1152\/ajpcell.00773.2024","volume":"328","author":"LJ Novinger","year":"2025","unstructured":"Novinger, L. J., Weinzierl, N. M. & Bonetto, A. Diversity in chemotherapy-induced cachexia. Am. J. Physiol. Cell Physiol. 328, C139\u2013c147 (2025).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10441_CR13","doi-asserted-by":"crossref","unstructured":"Thakir, T. M. et al. Cancer therapy and cachexia. J. Clin. Invest. 135, e191934 (2025).","DOI":"10.1172\/JCI191934"},{"key":"10441_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/science.adm8857","volume":"388","author":"XA Zhu","year":"2025","unstructured":"Zhu, X. A. et al. A neuroimmune circuit mediates cancer cachexia-associated apathy. Science 388, eadm8857 (2025).","journal-title":"Science"},{"key":"10441_CR15","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland, E. J. et al. Management of cancer cachexia: ASCO guideline. J. Clin. Oncol. 38, 2438\u20132453 (2020).","journal-title":"J. Clin. Oncol."},{"key":"10441_CR16","doi-asserted-by":"crossref","unstructured":"Barreto, R. et al. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs. Oncotarget 7, 43442\u201343460 (2016)","DOI":"10.18632\/oncotarget.9779"},{"key":"10441_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/jcsm.12360","volume":"10","author":"F Pin","year":"2019","unstructured":"Pin, F., Barreto, R., Couch, M. E., Bonetto, A. & O\u2019Connell, T. M. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia Sarcopenia Muscle 10, 140\u2013154 (2019).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10441_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4185-0","volume":"18","author":"EG Gebremedhn","year":"2018","unstructured":"Gebremedhn, E. G., Shortland, P. J. & Mahns, D. A. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer 18, 410 (2018).","journal-title":"BMC Cancer"},{"key":"10441_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/cncr.27732","volume":"119","author":"AA Argyriou","year":"2013","unstructured":"Argyriou, A. A. et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119, 438\u2013444 (2013).","journal-title":"Cancer"},{"key":"10441_CR20","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1002\/mco2.164","volume":"3","author":"YF Wang","year":"2022","unstructured":"Wang, Y. F., An, Z. Y., Lin, D. H. & Jin, W. L. Targeting cancer cachexia: molecular mechanisms and clinical study. MedComm. (2020) 3, e164 (2022).","journal-title":"MedComm. (2020)"},{"key":"10441_CR21","doi-asserted-by":"publisher","first-page":"43442","DOI":"10.18632\/oncotarget.9779","volume":"7","author":"R Barreto","year":"2016","unstructured":"Barreto, R. et al. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs. Oncotarget 7, 43442\u201343460 (2016).","journal-title":"Oncotarget"},{"key":"10441_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fphar.2017.00137","volume":"8","author":"JC Sorensen","year":"2017","unstructured":"Sorensen, J. C. et al. BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front Pharm. 8, 137 (2017).","journal-title":"Front Pharm."},{"key":"10441_CR23","doi-asserted-by":"crossref","unstructured":"Du, J. et al. Identification drug targets for oxaliplatin-induced cardiotoxicity without affecting cancer treatment through inter variability cross-correlation analysis (IVCCA). bioRxiv, 2024.2002. 2011.579390 (2024).","DOI":"10.1101\/2024.02.11.579390"},{"key":"10441_CR24","doi-asserted-by":"publisher","first-page":"L933","DOI":"10.1152\/ajplung.00256.2011","volume":"302","author":"J Liang","year":"2012","unstructured":"Liang, J. et al. A macrophage subpopulation recruited by CC chemokine ligand-2 clears apoptotic cells in noninfectious lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 302, L933\u2013L940 (2012).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10441_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/JLB.2MR0220-549R","volume":"108","author":"TM Bui","year":"2020","unstructured":"Bui, T. M., Wiesolek, H. L. & Sumagin, R. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J. Leukoc. Biol. 108, 787\u2013799 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"10441_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bbi.2020.12.026","volume":"93","author":"J Winneberger","year":"2021","unstructured":"Winneberger, J. et al. Platelet endothelial cell adhesion molecule-1 is a gatekeeper of neutrophil transendothelial migration in ischemic stroke. Brain Behav. Immun. 93, 277\u2013287 (2021).","journal-title":"Brain Behav. Immun."},{"key":"10441_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1096\/fj.03-0610com","volume":"18","author":"SH Lecker","year":"2004","unstructured":"Lecker, S. H. et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39\u201351 (2004).","journal-title":"FASEB J."},{"key":"10441_CR28","unstructured":"Batista J\u00fanior, M. L. & Henriques, F. Adipose tissue remodeling during cancer cachexia. in Muscle Cells\u2014Recent Advances and Future Perspectives (ed. Valarmathi, M. T.) (IntechOpen, Rijeka, 2018)."},{"key":"10441_CR29","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1158\/0008-5472.CAN-06-4585","volume":"67","author":"T Agustsson","year":"2007","unstructured":"Agustsson, T. et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 67, 5531\u20135537 (2007).","journal-title":"Cancer Res."},{"key":"10441_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/ars.2022.0149","volume":"38","author":"JR Huot","year":"2023","unstructured":"Huot, J. R. et al. Targeting mitochondria and oxidative stress in cancer- and chemotherapy-induced muscle wasting. Antioxid. Redox Signal 38, 352\u2013370 (2023).","journal-title":"Antioxid. Redox Signal"},{"key":"10441_CR31","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1073\/pnas.1809105116","volume":"116","author":"A Chugunova","year":"2019","unstructured":"Chugunova, A. et al. LINC00116 codes for a mitochondrial peptide linking respiration and lipid metabolism. Proc. Natl. Acad. Sci. USA. 116, 4940\u20134945 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10441_CR32","doi-asserted-by":"crossref","unstructured":"Tilg, H., Ianiro, G., Gasbarrini, A. & Adolph, T. E. Adipokines: masterminds of metabolic inflammation. Nat. Rev. Immunol. 25, 250-265 (2025).","DOI":"10.1038\/s41577-024-01103-8"},{"key":"10441_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11154-021-09636-2","volume":"23","author":"M Maffei","year":"2022","unstructured":"Maffei, M. & Giordano, A. Leptin, the brain and energy homeostasis: From an apparently simple to a highly complex neuronal system. Rev. Endocr. Metab. Disord. 23, 87\u2013101 (2022).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10441_CR34","doi-asserted-by":"publisher","first-page":"828","DOI":"10.2337\/diabetes.48.4.828","volume":"48","author":"DG Baskin","year":"1999","unstructured":"Baskin, D. G., Breininger, J. F. & Schwartz, M. W. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 48, 828\u2013833 (1999).","journal-title":"Diabetes"},{"key":"10441_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.tem.2020.10.004","volume":"31","author":"L Rochette","year":"2020","unstructured":"Rochette, L., Zeller, M., Cottin, Y. & Vergely, C. Insights into mechanisms of GDF15 and receptor GFRAL: therapeutic targets. Trends Endocrinol. Metab. 31, 939\u2013951 (2020).","journal-title":"Trends Endocrinol. Metab."},{"key":"10441_CR36","doi-asserted-by":"crossref","unstructured":"Wagner, L. et al. The impact of neuregulin 4 on metabolic dysregulation in lipodystrophy. Endocrinology 166,bqaf159 1\u201315 (2025).","DOI":"10.1210\/endocr\/bqaf112"},{"key":"10441_CR37","doi-asserted-by":"crossref","unstructured":"Narasimhan, A. et al. Profiling of adipose and skeletal muscle in human pancreatic cancer cachexia reveals distinct gene profiles with convergent pathways. Cancers (Basel) 13, 1975\u20131997 (2021).","DOI":"10.3390\/cancers13081975"},{"key":"10441_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-758","volume":"14","author":"M Schupp","year":"2013","unstructured":"Schupp, M. et al. Metabolite and transcriptome analysis during fasting suggest a role for the p53-Ddit4 axis in major metabolic tissues. BMC Genom. 14, 758 (2013).","journal-title":"BMC Genom."},{"key":"10441_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-981-10-6020-5_11","volume":"1026","author":"N Shyh-Chang","year":"2017","unstructured":"Shyh-Chang, N. Metabolic changes during cancer cachexia pathogenesis. Adv. Exp. Med. Biol. 1026, 233\u2013249 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"10441_CR40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.tem.2012.10.006","volume":"24","author":"M Tsoli","year":"2013","unstructured":"Tsoli, M. & Robertson, G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol. Metab. 24, 174\u2013183 (2013).","journal-title":"Trends Endocrinol. Metab."},{"key":"10441_CR41","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet. Oncol. 12, 489\u2013495 (2011).","journal-title":"Lancet. Oncol."},{"key":"10441_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.683168","volume":"2","author":"UO Warncke","year":"2021","unstructured":"Warncke, U. O. et al. Impact of dose, sex, and strain on oxaliplatin-induced peripheral neuropathy in mice. Front Pain. Res. (Lausanne) 2, 683168 (2021).","journal-title":"Front Pain. Res. (Lausanne)"},{"key":"10441_CR43","doi-asserted-by":"publisher","first-page":"e54161","DOI":"10.1371\/journal.pone.0054161","volume":"8","author":"LE Ta","year":"2013","unstructured":"Ta, L. E. et al. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One 8, e54161 (2013).","journal-title":"PLoS One"},{"key":"10441_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.14302\/issn.2372-6601.jhor-25-5944","volume":"4","author":"LC Sudlow","year":"2026","unstructured":"Sudlow, L. C., Du, J., Shahverdi, K., Zhou, H. & Berezin, M. Y. Lineage-specific disruption of hematopoiesis by oxaliplatin: mechanisms of erythropoietin resistance and immune suppression. J. Hematol. Oncol. Res. 4, 38\u201352 (2026).","journal-title":"J. Hematol. Oncol. Res"},{"key":"10441_CR45","doi-asserted-by":"crossref","unstructured":"Wang, Z., Sudlow, L. C., Du, J. & Berezin, M. Y. ThematicGO: A Keyword-Based Framework for Interpreting Gene Ontology Enrichment via Biological Themes. bioRxiv, 2026.2002.2008.704666 (2026).","DOI":"10.64898\/2026.02.08.704666"},{"key":"10441_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neulet.2013.03.033","volume":"544","author":"J Guindon","year":"2013","unstructured":"Guindon, J. & Hohmann, A. G. Use of sodium bicarbonate to promote weight gain, maintain body temperature, normalize renal functions and minimize mortality in rodents receiving the chemotherapeutic agent cisplatin. Neurosci. Lett. 544, 41\u201346 (2013).","journal-title":"Neurosci. Lett."},{"key":"10441_CR47","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.psyneuen.2012.10.010","volume":"38","author":"JI Granger","year":"2013","unstructured":"Granger, J. I., Ratti, P. L., Datta, S. C., Raymond, R. M. & Opp, M. R. Sepsis-induced morbidity in mice: effects on body temperature, body weight, cage activity, social behavior and cytokines in brain. Psychoneuroendocrinology 38, 1047\u20131057 (2013).","journal-title":"Psychoneuroendocrinology"},{"key":"10441_CR48","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1128\/IAI.67.12.6603-6610.1999","volume":"67","author":"S Ebong","year":"1999","unstructured":"Ebong, S. et al. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect. Immun. 67, 6603\u20136610 (1999).","journal-title":"Infect. Immun."},{"key":"10441_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1089107","volume":"2019","author":"DW Jekarl","year":"2019","unstructured":"Jekarl, D. W. et al. Diagnosis and prognosis of sepsis based on use of cytokines, chemokines, and growth factors. Dis. Markers 2019, 1089107 (2019).","journal-title":"Dis. Markers"},{"key":"10441_CR50","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9, J. & Sheppard, D. TGF-\u03b2 signaling in health and disease. Cell 186, 4007\u20134037 (2023).","journal-title":"Cell"},{"key":"10441_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","volume":"170","author":"HJ Patel","year":"2017","unstructured":"Patel, H. J. & Patel, B. M. TNF-\u03b1 and cancer cachexia: molecular insights and clinical implications. Life Sci. 170, 56\u201363 (2017).","journal-title":"Life Sci."},{"key":"10441_CR52","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.phrs.2016.11.025","volume":"115","author":"Z Szondy","year":"2017","unstructured":"Szondy, Z. & Pallai, A. Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: Therapeutic implications. Pharm. Res. 115, 124\u2013132 (2017).","journal-title":"Pharm. Res."},{"key":"10441_CR53","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s001090000137","volume":"78","author":"G Mantovani","year":"2000","unstructured":"Mantovani, G. et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J. Mol. Med. (Berl.) 78, 554\u2013561 (2000).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10441_CR54","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1046\/j.1471-4159.2001.00639.x","volume":"79","author":"C Bing","year":"2001","unstructured":"Bing, C., Taylor, S., Tisdale, M. J. & Williams, G. Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J. Neurochem. 79, 1004\u20131012 (2001).","journal-title":"J. Neurochem"},{"key":"10441_CR55","first-page":"4493","volume":"59","author":"A Inui","year":"1999","unstructured":"Inui, A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 59, 4493\u20134501 (1999).","journal-title":"Cancer Res."},{"key":"10441_CR56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1042\/cs0930273","volume":"93","author":"JP Simons","year":"1997","unstructured":"Simons, J. P., Schols, A. M., Campfield, L. A., Wouters, E. F. & Saris, W. H. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin. Sci. (Lond.) 93, 273\u2013277 (1997).","journal-title":"Clin. Sci. (Lond.)"},{"key":"10441_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2416453","volume":"16","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models. MAbs 16, 2416453 (2024).","journal-title":"MAbs"},{"key":"10441_CR58","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/jcsm.13219","volume":"14","author":"BY Lee","year":"2023","unstructured":"Lee, B. Y. et al. GDNF family receptor alpha-like antagonist antibody alleviates chemotherapy-induced cachexia in melanoma-bearing mice. J. Cachexia Sarcopenia Muscle 14, 1441\u20131453 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10441_CR59","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jcsm.12077","volume":"7","author":"L Lerner","year":"2016","unstructured":"Lerner, L. et al. MAP3K11\/GDF15 axis is a critical driver of cancer cachexia. J. Cachexia Sarcopenia Muscle 7, 467\u2013482 (2016).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10441_CR60","doi-asserted-by":"crossref","unstructured":"Groarke, J. D. et al. Ponsegromab for the treatment of cancer cachexia. N. Engl. J. Med. 391, 2291\u20132303, (2024).","DOI":"10.1056\/NEJMoa2409515"},{"key":"10441_CR61","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s11914-020-00628-w","volume":"18","author":"X Zhong","year":"2020","unstructured":"Zhong, X. & Zimmers, T. A. Sex differences in cancer cachexia. Curr. Osteoporos. Rep. 18, 646\u2013654 (2020).","journal-title":"Curr. Osteoporos. Rep."},{"key":"10441_CR62","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1152\/japplphysiol.00196.2023","volume":"135","author":"AR Cabrera","year":"2023","unstructured":"Cabrera, A. R. et al. Females display relatively preserved muscle quality compared with males during the onset and early stages of C26-induced cancer cachexia. J. Appl Physiol. (1985) 135, 655\u2013672 (2023).","journal-title":"J. Appl Physiol. (1985)"},{"key":"10441_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-023-09462-7","volume":"24","author":"F Morena da Silva","year":"2023","unstructured":"Morena da Silva, F. et al. The time-course of cancer cachexia onset reveals biphasic transcriptional disruptions in female skeletal muscle distinct from males. BMC Genom. 24, 374 (2023).","journal-title":"BMC Genom."},{"key":"10441_CR64","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-022-03298-y","volume":"78","author":"S De Francia","year":"2022","unstructured":"De Francia, S. et al. Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities? Eur. J. Clin. Pharm. 78, 1029\u20131038 (2022).","journal-title":"Eur. J. Clin. Pharm."},{"key":"10441_CR65","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1093\/jnci\/djaf281","volume":"117","author":"E Cheng","year":"2025","unstructured":"Cheng, E. et al. Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB\/SWOG 80702 (Alliance). J. Natl. Cancer Inst. 117, 2643\u20132652 (2025).","journal-title":"J. Natl. Cancer Inst."},{"key":"10441_CR66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27\u201331 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"10441_CR67","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/bloodadvances.2025017296","volume":"10","author":"MR Dyer","year":"2026","unstructured":"Dyer, M. R. et al. Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model. Blood Adv. 10, 343\u2013355 (2026).","journal-title":"Blood Adv."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10441-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10441-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10441-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:02:57Z","timestamp":1790121777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10441-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10441"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10441-3","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: M.Y.B. is a consultant for Sarya LLC and Daxor Inc and a founder of HSpeQ LLC. J.R.B. is a member of the Scientific Advisory Board of LUCA Science, Inc.; receives research support from LUCA Science and Edgewise Therapeutics; is a consultant for Columbus Instruments; has consulted for DeciBio within the past 12 months (discontinued); receives royalties from Springer Nature Group; is an inventor on technology licensed to Columbus Instruments with royalty rights; and is an inventor on pending patent applications related to the treatment of metabolic diseases (63\/625,555), allergic diseases (US20210128689A1) and mitochondria transfer (018984\/US). The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1241"}}